Identification and management of subclinical disease activity in early multiple sclerosis: a review

D Ontaneda, T Chitnis, K Rammohan, AZ Obeidat - Journal of Neurology, 2024 - Springer
Importance Early treatment initiation in multiple sclerosis (MS) is crucial in preventing
irreversible neurological damage and disability progression. The current assessment of …

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

M Filippi, R Danesi, T Derfuss, M Duddy, P Gallo… - Journal of …, 2022 - Springer
Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best
strategy to delay irreversible neurological damage and progression of multiple sclerosis …

Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

BA Singer, J Feng, H Chiong-Rivero - Journal of Neurology, 2024 - Springer
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …

Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

H Inojosa, D Schriefer, NH Ness, A Dillenseger… - Journal of …, 2025 - Springer
Background Natalizumab (NAT) is an established disease-modifying therapy (DMT) for
highly active multiple sclerosis (MS). However, its use involves complex decision-making …

The pressing need for imaging biomarkers of disability progression in multiple sclerosis

P Naval-Baudin, P Arroyo-Pereiro, C Majós - European Radiology, 2024 - Springer
Multiple sclerosis (MS) is a degenerative and inflammatory central nervous system disease.
It predominantly affects younger adults, can be severely disabling, and has a prolonged …